Biogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
7,500
Employees7,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
7,500
Employees7,500

BIIB Key Statistics

Market cap
31.18B
Market cap31.18B
Price-Earnings ratio
37.16
Price-Earnings ratio37.16
Dividend yield
Dividend yield
Average volume
827.77K
Average volume827.77K
High today
$211.00
High today$211.00
Low today
$209.98
Low today$209.98
Open price
$210.99
Open price$210.99
Volume
5.46K
Volume5.46K
52 Week high
$219.72
52 Week high$219.72
52 Week low
$131.52
52 Week low$131.52

Stock Snapshot

The current Biogen(BIIB) stock price is $211.00, with a market capitalization of 31.18B. The stock trades at a price-to-earnings (P/E) ratio of 37.16.

On 2026-08-18, Biogen(BIIB) stock moved within a range of $209.98 to $211.00. With shares now at $211.00, the stock is trading +0.5% above its intraday low and 0.0% below the session's peak.

Trading activity shows a volume of 5.46K, compared to an average daily volume of 827.77K.

The stock's 52-week range extends from a low of $131.52 to a high of $219.72.

The stock's 52-week range extends from a low of $131.52 to a high of $219.72.

BIIB News

MarketWatch 6d
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

...

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
TipRanks 7d
Biogen’s Long-Term Spinraza Study Wraps Up, Setting the Stage for Key SMA Data

Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

Analyst ratings

67%

of 36 ratings
Buy
66.7%
Hold
30.6%
Sell
2.8%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.